Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1996 Jun;34(6):1462–1464. doi: 10.1128/jcm.34.6.1462-1464.1996

Detection of quinolone-resistant Neisseria gonorrhoeae.

K M Kam 1, P W Wong 1, M M Cheung 1, N K Ho 1
PMCID: PMC229042  PMID: 8735098

Abstract

The present National Committee for Clinical Laboratory Standards (NCCLS) guideline for testing Neisseria gonorrhoeae quinolone susceptibility defines only a susceptible category for ciprofloxacin, enoxacin, lomefloxacin, and ofloxacin, while susceptible, intermediate, and resistant categories are defined for fleroxacin. To further define the criteria for detection of quinolone resistance in gonococci, by standard disk diffusion and agar dilution methodologies recommended by the NCCLS, we tested 29 strains of quinolone-resistant N. gonorrhoeae (QRNG) recently isolated from ofloxacin-treated patients who were considered clinical failures. Regression analyses were performed on these results together with those of another 20 strains showing reduced susceptibility and 13 fully susceptible strains (ofloxacin MICs of < or = 0.25 microgram/ml). With 5-micrograms ofloxacin disks, resistance in 27 (93.1%) of the QRNG strains (MICs of > 1 microgram/ml) was detected by the criterion of a zone diameter of < 22 mm, while in the remaining 2 (6.9%), the disks failed to detect resistance. A cluster of 15 highly resistant strains showed ofloxacin MICs of > 4 micrograms/ml and zone diameters of < 13 mm. When tested with 5-micrograms ciprofloxacin disks, the corresponding values for resistance and high-level resistance of these QRNG strains were < 25 mm (MICs of > 0.5 micrograms/ml) and < 15 mm (MICs of > 2 micrograms /ml), respectively. Six strains for which ofloxacin MICs were > or = 8 micrograms/ml showed no zones at all with both 5-micrograms ofloxacin and 5-micrograms ciprofloxacin disks. These QRNG strains are now firmly established in the Southeast Asia region, and it is important for clinical laboratories to recognize these clinically resistant strains and to monitor their spread.

Full Text

The Full Text of this article is available as a PDF (235.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Jones R. N. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations. Antimicrob Agents Chemother. 1984 Jun;25(6):775–777. doi: 10.1128/aac.25.6.775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Black J. R., Long J. M., Zwickl B. E., Ray B. S., Verdon M. S., Wetherby S., Hook E. W., 3rd, Handsfield H. H. Multicenter randomized study of single-dose ofloxacin versus amoxicillin-probenecid for treatment of uncomplicated gonococcal infection. Antimicrob Agents Chemother. 1989 Feb;33(2):167–170. doi: 10.1128/aac.33.2.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boslego J. W., Hicks C. B., Greenup R., Thomas R. J., Wiener H. A., Ciak J., Tramont E. C. A prospective randomized trial of ofloxacin vs. doxycycline in the treatment of uncomplicated male urethritis. Sex Transm Dis. 1988 Oct-Dec;15(4):186–191. doi: 10.1097/00007435-198810000-00002. [DOI] [PubMed] [Google Scholar]
  4. Clendennen T. E., Echeverria P., Saengeur S., Kees E. S., Boslego J. W., Wignall F. S. Antibiotic susceptibility survey of Neisseria gonorrhoeae in Thailand. Antimicrob Agents Chemother. 1992 Aug;36(8):1682–1687. doi: 10.1128/aac.36.8.1682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Erwin M. E., Jones R. N. Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium. J Clin Microbiol. 1992 May;30(5):1170–1173. doi: 10.1128/jcm.30.5.1170-1173.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fuchs P. C., Barry A. L., Baker C., Murray P. R., Washington J. A., 2nd Proposed interpretive criteria and quality control parameters for testing in vitro susceptibility of Neisseria gonorrhoeae to ciprofloxacin. J Clin Microbiol. 1991 Oct;29(10):2111–2114. doi: 10.1128/jcm.29.10.2111-2114.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fuchs P. C., Barry A. L., Jones R. N., Thornsberry C. Proposed disk diffusion susceptibility criteria for ofloxacin. J Clin Microbiol. 1985 Aug;22(2):310–311. doi: 10.1128/jcm.22.2.310-311.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jephcott A. E., Turner A. Ciprofloxacin resistance in gonococci. Lancet. 1990 Jan 20;335(8682):165–165. doi: 10.1016/0140-6736(90)90035-4. [DOI] [PubMed] [Google Scholar]
  9. Jones R. N., Gavan T. L., Thornsberry C., Fuchs P. C., Gerlach E. H., Knapp J. S., Murray P., Washington J. A., 2nd Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline. J Clin Microbiol. 1989 Dec;27(12):2758–2766. doi: 10.1128/jcm.27.12.2758-2766.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kam K. M., Lo K. K., Ho N. K., Cheung M. M. Rapid decline in penicillinase-producing Neisseria gonorrhoeae in Hong Kong associated with emerging 4-fluoroquinolone resistance. Genitourin Med. 1995 Jun;71(3):141–144. doi: 10.1136/sti.71.3.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kam K. M., Lo K. K., Lai C. F., Lee Y. S., Chan C. B. Ofloxacin susceptibilities of 5,667 Neisseria gonorrhoeae strains isolated in Hong Kong. Antimicrob Agents Chemother. 1993 Sep;37(9):2007–2008. doi: 10.1128/aac.37.9.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kumamoto Y., Sakai S., Hirose T., Tsunekawa T., Machida T., Kiyota H., Okazaki T., Kishi H., Higashihara E., Aso Y. [Efficacy of ofloxacin in sexually transmitted male urethritis and cervicitis]. Jpn J Antibiot. 1988 Oct;41(10):1445–1479. [PubMed] [Google Scholar]
  13. Ringertz S., Rylander M., Kronvall G. Disk diffusion method for susceptibility testing of Neisseria gonorrhoeae. J Clin Microbiol. 1991 Aug;29(8):1604–1609. doi: 10.1128/jcm.29.8.1604-1609.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Tanaka M., Kumazawa J., Matsumoto T., Kobayashi I. High prevalence of Neisseria gonorrhoeae strains with reduced susceptibility to fluoroquinolones in Japan. Genitourin Med. 1994 Apr;70(2):90–93. doi: 10.1136/sti.70.2.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Young H., Moyes A., Tait I. B., McCartney A. C., Gallacher G. Non-typable quinolone-resistant gonococci. Lancet. 1990 Mar 10;335(8689):604–604. doi: 10.1016/0140-6736(90)90385-i. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES